Psychology in the Prescription Era: Building a Firewall between Marketing and Science

American Psychologist

Volumn 58, Issue 12, 2003, Pages 1028-1043

  Antonuccio, David O ^a   Danton, William G ^a   McClanahan, Terry Michael ^b  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^b KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERTIZING; CONFLICT OF INTEREST; DRUG INDUSTRY; GOVERNMENT; HEALTH CARE ORGANIZATION; HUMAN; PATIENT EDUCATION; PSYCHOLOGY; REVIEW; SCIENCE;

ADVERTISING; CONFLICT OF INTEREST; DRUG INDUSTRY; FEDERAL GOVERNMENT; HUMANS; PATIENT EDUCATION; PSYCHOLOGY; SCIENCE; SOCIETIES;

EID: 0346991516     PISSN: 0003066X     EISSN: None     Source Type: Journal    
DOI: 10.1037/0003-066X.58.12.1028     Document Type: Review

References (154)

1. Abassi, K., & Smith, R. (2003). No more free lunches. British Medical Journal, 326, 1155-1156.
2. Accreditation Council on Continuing Medical Education. (2002, July 11). Standards to ensure the separation of promotion from education within the CME activities of ACCME accredited providers. Retrieved from http://www.accme.org/incoming/SCS_Draft_Jan_2003.pdf
3. Als-Nielsen, B., Chen, W., Gluud, C., & Kjaergard, L. L. (2003). Association of funding and conclusions in randomized drug trials: A reflection of treatment effect or adverse events? Journal of the American Medical Association, 290, 921-928.
4. Altman, L. K. (1999, August 24). The doctor's world: Inside medical journals, a rising quest for profits. The New York Times. Retrieved from http://www.nytimes.com/library/national/science/082499hth-doctors.html
5. American Medical Student Association. (2002). AMSA policy on pharmaceutical promotions. Retrieved from http://www.amsa.org/prof/policy.cfm
6. Angell, M. (2000). Is academic medicine for sale? New England Journal of Medicine, 342, 1516-1518.
7. Antonuccio, D. O., Burns, D. D., & Danton, W. G. (2002), Antidepressants: A triumph of marketing over science? Prevention & Treatment, 5, Article 25. Retrieved from http://www.journals.apa.org/prevention/volume5/pre0050025c.html
8. Antonuccio, D. O., & Danton, W. G. (2002). A psychology manifesto for the prescription era. Nevada State Psychological Association Bulletin, 7, 8-9.
9. Antonuccio, D. O., & Danton, W. G. (2003). Prescription privileges 102: Biting the hand that's trying to feed you. The Clinical Psychologist, 56, 17-18.
10. Antonuccio, D. O., Danton, W. G., DeNelsky, G. Y., Greenberg, R. P., & Gordon, J. S. (1999). Raising questions about antidepressants. Psychotherapy and Psychosomatics, 68, 3-14.
11. Axelrod, J., Ban, T. A., Battegay, R., Bech, P., Berrios, G. E., Bolwig, T., et al. (2001). Academic freedom: Eminent physicians protest treatment of Dr. David Healy. Retrieved from http://www.caut.ca/english/issues/acadfreedom/healyletter.asp
12. Bahl, S., Cotterchio, M., & Kreiger, N. (2003). Use of antidepressant medications and the possible association with breast cancer risk. Psychotherapy and Psychosomatics, 72, 185-194.
13. Bekelman, J. E., Li, Y., & Gross, C. P. (2003). Scope and impact of financial conflicts of interest in biomedical research. Journal of the American Medical Association, 289, 454-465.
14. Beutler, L. (2002). Prescriptive authority: Moving toward a new clinical psychology? The Clinical Psychologist, 55, 1-3.
15. Blumenthal, D., Campbell, E. G., Anderson, M. S., Causino, N., & Louis, K. S. (1997). Withholding research results in academic life science: Evidence from a national survey of faculty. Journal of the American Medical Association, 277, 1224-1228.
16. Bodenheimer, T. (2000). Uneasy alliance - clinical investigators and the pharmaceutical industry. New England Journal of Medicine, 342, 1539-1544.
17. Boseley, S. (2002, May 21). Bitter pill. The Guardian. Retrieved from http://www.guardian.co.uk/Archive/Article/0,4273,4417163,00.html
18. Boseley, S. (2003, March 17). Drugs inquiry links to makers. The Guardian. Retrieved from http://www.society.guardian.co.uk/print/0,3858,4626619-103690,00.html
19. Brennan, T. A. (1994). Buying editorials. New England Journal of Medicine, 331, 673-675.
20. Callaham, M. L., Wears, R. L., Weber, E. J., Barton, C., & Young, G. (1998). Positive-outcome bias and other limitations in the outcome of research abstracts submitted to a scientific meeting. Journal of the American Medical Association, 280, 254-257.
21. Campbell, E. G., Louis, K. S., & Blumenthal, D. (1998). Looking a gift horse in the mouth: Corporate gifts supporting life sciences research. Journal of the American Medical Association. 279, 995-999.
22. Campbell, E. G., Weissman, J. S., Blarridge, B., Yucel, R., Causino, N., & Blumenthal, D. (2003). Characteristics of medical school faculty members serving on institutional review boards: Results of a national survey. Academic Medicine, 78, 831-836.
23. Cauchon, D. (2000, September 25). FDA advisers tied to industry. USA Today. Retrieved from http://www.commondreams.org/headlines/092500-01.htm
24. Cech, T. R., & Leonard, J. S. (2001). Conflict of interest - Moving beyond disclosure. Science, 291, 989-990.
25. Chalmers, I., (2000). Current controlled trials: An opportunity to help improve the quality of clinical research. Current Controlled Trials in Cardiovascular Medicine, 1, 3-8.
26. Chopra, S. S. (2003). Industry funding of clinical trials. Journal of the American Medical Association, 290, 113-114.
27. Choudhry, N. K., Stelfox, H. T., & Detsky, A. S. (2002). Relationships between authors of clinical practice guidelines and the pharmaceutical industry. Journal of the American Medical Association, 287, 612-617.
28. Christensen, R. C., & Tueth, M. J. (1998). Pharmaceutical companies and academic departments of psychiatry: A call for ethics education. Academic Psychiatry, 22, 135-137.
29. Cimons, M. (1999). NIH opens conflict-of-interest investigation. Nature Medicine, 5, 129-130.
30. Coyle, S. (2002). Physician-industry relations. Annals of Internal Medicine, 136, 396-406.
31. Dana, J., & Loewenstein, G. (2003). A social science perspective on gifts to physicians from industry. Journal of the American Medical Association, 290, 252-255.
32. Davidoff, F., DeAngelis, C. D., Drazen, J. M., Nicholls, M. G., Hoey, J., Hojgaard, L., et al. (2001). Sponsorship, authorship, and accountability. New England Journal of Medicine, 345, 825-827.
33. Daw, J. (2002). New Mexico becomes first state to gain Rx privileges. Monitor on Psychology, 33, 24-25.
34. DeAngelis, C. D., Fontanarosa, P. B., & Flanagin, A. (2001). Reporting financial conflicts of interest and relationships between investigators and research sponsors. Journal of the American Medical Association, 286, 89-91.
35. DeLeon, P. H., & Wiggins, J. G. (1996). Prescription privileges for psychologists. American Psychologist, 51, 225-229.
36. Deyo, R. A., Psaty, B. M., Simon, G., Wagner, E. H., & Omenn, G. S. (1997). The messenger under attack - Intimidation of researchers by special-interest groups. New England Journal of Medicine, 336, 1176-1179.
37. Dickersin, K., & Rennie, D. (2003). Registering clinical trials. Journal of the American Medical Association, 290, 516-523.
38. Drazen, J. M., & Curfman, G. D. (2002). Financial associations of authors. New England Journal of Medicine, 346, 1901-1902.
39. Elliot, C. (2001). Pharma buys a conscience. The American Prospect, 12, 1-9.
40. Even, C., Siobud-Dorocant, E., & Dardennes, R. M. (2000). Critical approach to antidepressant trials: Blindness protection is necessary, feasible, and measurable. British Journal of Psychiatry, 177, 47-51.
41. Farrelly, M. C., Healton, C. G., Davis, K. C., Messeri, P., Hersey, J. C., & Haviland, M. L. (2002). Getting to the truth: Evaluating national tobacco countermarketing campaigns. American Journal of Public Health, 92, 901-907.
42. Fava, G. A. (1998). All our dreams are sold. Psychotherapy and Psychosomatics, 67, 191-193.
43. Fava, G. A. (2001). Conflict of interest in special interest groups: The making of a counter culture. Psychotherapy and Psychosomatics, 70, 1-5.
44. Fava, G. A. (2002). Long-term treatment with antidepressant drugs: The spectacular achievements of propaganda. Psychotherapy and Psychosomatics, 71, 127-132.
45. Flanagin, A., Carey, L. A., Fontanarosa, P. B., Phillips, S. G., Pace, B. P., Lundberg, G. D., & Rennie, D. (1998). Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals. Journal of the American Medical Association, 280, 222-224.
46. Food and Drug Administration. (2003). FDA statement regarding the anti-depressant Paxil for pediatric population. Retrieved June 19, 2003 from http://www.fda.gov/bbs/topics/ANSWERS/2003ANS01230.html
47. Fortune. (2000, April 17). How the industries stack up. Retrieved from http://www.fortune.com/indexw.jhtml?channel=artcol.jhtml&doc_id=00001423
48. Free rein for drug ads? (2003, February). Consumer Reports, pp. 33-37.
49. Friedman, R. A. (2002, December 17). Curing and killing: The perils of a growing medicine cabinet. The New York Times. Retrieved from http://www.3sistersapothecary.com/html/resources/library/curing.cfm
50. Gandhi, T. K., Weingart, S. N., Borus, J., Seger, A. C., Peterson, J., Burdick, E., et al. (2003). Adverse drug events in ambulatory care. New England Journal of Medicine, 348, 1556-1564.
51. Gilbody, S. M., & Song, F. (2000). Publication bias and the integrity of psychiatry research. Psychological Medicine, 30, 253-258.
52. Gram, L. F. (1994). Fluoxetine. New England Journal of Medicine, 331, 1354-1361.
53. Greenberg, R. P., Bornstein, R. F., Greenberg, M. D., & Fisher, S. (1992). A meta-analysis of antidepressant outcome under "blinder" conditions. Journal of Consulting and Clinical Psychology, 60, 664-669.
54. Greenberg, R. P., & Fisher, S (1997). Mood-mending medicines: Probing drug, psychotherapy, and placebo solutions. In S. Fisher & R. P. Greenberg (Eds.), From placebo to panacea: Putting psychiatric drugs to the test (pp. 115-172). New York: Wiley.
55. Gurwitz, J. H., Field, T. S., Harrold, L. R., Rothschild, J., Debellis, K., Seger, A. C., et al. (2003). Incidence and preventability of adverse drug events among older persons in the ambulatory setting. Journal of the American Medical Association, 289, 1107-1116.
56. Healy, D. (2001). The dilemmas posed by new and fashionable treatments. Advances in Psychiatric Treatment, 7, 322-327.
57. Healy, D. (2002). Conflicting interests in Toronto: Anatomy of a controversy at the interface of academia and industry. Perspectives in Biology and Medicine, 45, 250-263.
58. Healy, D. (2003). Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychotherapy and Psychosomatics, 72, 71-79.
59. Healy, D., & Catell, D. (2003). Interface between authorship, industry and science in the domain of therapeutics. British Journal of Psychiatry. 183, 22-27.
60. Heiser, N. A., Turner, S. M., & Beidel, D. C. (2003). Shyness: Relationship to social phobia and other psychiatric disorders. Behavior Research and Therapy, 41, 209-221.
61. Herxheimer, A. (2003). Relationships between the pharmaceutical industry and patients' organizations. British Medical Journal, 326, 1208-1210.
62. Horton R. (2001). Lotronex and the FDA: A fatal erosion of integrity. Lancet, 357, 1544-1545.
63. Johns, M. M. E., Barnes, M., & Florencio, P. S. (2003). Restoring balance to industry-academia relationships in an era of institutional financial conflicts of interest: Promoting research while maintaining trust. Journal of the American Medical Association, 289, 741-746.
64. Joseph A. M., & Antonuccio, D. O. (1999). Lack of efficacy of transdermal nicotine in smoking cessation. New England Journal of Medicine, 341, 1157-1158.
65. Joseph, A. M., Norman S. M., Ferry L. H., Prochazka A. V., Westman E. C., Steele B. G., et al. (1996). The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. New England Journal of Medicine, 335, 1792-1798.
66. Juurlink, D. N., Mamdani, M., Kopp, A., Laupacis, A., & Redelmeier, D. A. (2003). Drug-drug interactions among elderly patients hospitalized for drug toxicity. Journal of the American Medical Association, 289, 1652-1658.
67. Keller, M. B., McCullough, J. P., Klein, D. N., Arnow, B., Dunner, D. L., Gelenberg, A. J., et al. (2000). A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. New England Journal of Medicine, 18, 1462-1470.
68. Khan, A., Khan, S., & Brown, W. A. (2002). Are placebo controls necessary to test new antidepressants and anxiolytics? International Journal of Neuropsychopharmacology, 5, 193-197.
69. Kirsch, I., Moore, T. J., Scoboria, A., & Nicholls, S. S. (2002). The emperor's new drugs: An analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prevention & Treatment, 5, Article 23. Retrieved from http://www.journals.apa.org/prevention/volume5/pre00.50023a.html
70. Klein, D. F. (2000). Flawed meta-analyses comparing psychotherapy with pharmacotherapy. American Journal of Psychiatry, 157, 1204-1211.
71. Klein D. F., Thase, M. E., Endicott, J., Adler, L., Glick, I., Kalali, A., et al. (2002). Improving clinical trials: American Society of Clinical Psychopharmacology recommendations. Archives of General Psychiatry, 59, 272-278.
72. Koerner, B. I. (2002, July/August). Disorders made to order. Mother Jones, 58-64.
73. Kowalczyk, L. (2003, May 25). Drug companies' secret reports outrage doctors. The Boston Globe, p. A1.
74. Kranish, M. (2002, December 22). FDA counsel's rise embodies US shift. The Boston Globe, p. A1.
75. Krimsky, S., & Rothenberg, L. S. (2001). Conflict of interest policies in science and medical journals: Editorial practices and author disclosures. Science and Engineering Ethics, 7, 205-218.
76. Krimsky, S., Rothenberg, L. S., Stott, P., & Kyle, G. (1998). Scientific journals and their authors' financial interests: A pilot study. Psychotherapy and Psychosomatics, 67, 194-201.
77. Kroenke, K., West, S. L., Swindle, R., Gilsenan, A., Eckert, G. J., Dolor, R., et al. (2001). Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care. Journal of the American Medical Association, 286, 2947-2955.
78. Landman, A., Ling, P. M., & Glantz, S. A. (2002). Tobacco industry youth smoking prevention programs: Protecting the industry and hurting tobacco control. American journal of Public Health, 92, 917-930.
79. Langer, G. (2000, April 10). Use of antidepressants is a long-term practice. ABCNEWS.com. Retrieved from http://abcnews.go.com/onair/WorldNewsTonight/poll000410.html
80. Lasser, K. E., Allen, P. D., Woolhandler, S. J., Himmelstein, D. U., Wolfe, S. M., & Bor D. H. (2002). Timing of new black box warnings and withdrawals for prescription medications. Journal of the American Medical Association, 287, 2215-2220.
81. Laughren, T. P. (2001). The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: An FDA perspective. European Psychiatry, 16, 418-423.
82. Lazarou, J., Pemeranz, B., & Corey, P. N. (1998). Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. Journal of the American Medical Association, 279, 1200-1205.
83. Letter to Academic Press. (2002, November 19). Re: Regulatory toxicology and pharmacology. Retrieved from http://www.cspinet.org/new/ 200211191.html
84. Levant, R. F., & Sammons, M. T. (2003). What history 103 can teach us about psychopharmacology 102: A reply to Healy. The Clinical Psychologist, 56, 21-22.
85. Levinsky, N. G. (2002). Nonfinancial conflicts of interest in research. New England Journal of Medicine, 347, 759-761.
86. Lexchin, J., Bero, L. A., Djulbegovic, B., & Clark, O. (2003). Pharmaceutical industry sponsorship and research outcome and quality: systematic review. British Medical Journal, 326, 1167-1170.
87. Lo, B., Wolf, L. E., & Berkeley, A. (2000). Conflict-of-interest policies for investigators in clinical trials. New England Journal of Medicine, 343, 1643-1645.
88. Loke, T. W., Koh, F. C., & Ward, J. E. (2002). Pharmaceutical advertisement claims in Australian medical publications: Is evidence accessible, compelling and communicated comprehensively? Medical Journal of Australia, 177, 291-293.
89. Louie, L. (2001, May). A prescription for profits. Upside, 102-107.
90. Marks, I. M., Swinson, R. P., Basoglu, M., Kuch, K., Noshirvani, H., O'Sullivan, G., et al. (1993). Alprazolam and exposure alone and combined in panic disorder with agoraphobia: A controlled study in London and Toronto. British Journal of Psychiatry, 162, 776-787.
91. Marks, I. M., Swinson, R. P., Basoglu, M., Noshirvani, H., Kuch, K., O'Sullivan, G., & Lelliott, P. T. (1993b). Reply to comment on the London/Toronto Study. British Journal of Psychiatry, 162, 790-794.
92. Melander, H., Ahlqvist-Rastad, J., Meijer, G., & Beermann, B. (2003). Evidence b(i)ased medicine-selective reporting from studies sponsored by pharmaceutical industry: Review of studies in new drug applications. British Medical Journal, 326, 1171-1173.
93. Mello, M. M., Rosenthal, M., & Neumann, P. J. (2003). Direct-to-consumer advertising and shared liability for pharmaceutical manufacturers, Journal of the American Medical Association, 289, 477-481.
94. Mintzes, B., Bonaccorso, S. N., & Sturchio, J. L. (2002). For and against: Direct to consumer advertising is medicalising normal human experience. British Medical Journal, 324, 908-911.
95. Miracle drugs or media drugs? (1992, March). Consumer Reports, 142-146.
96. Misakian, A. L., & Bero, L. A. (1998). Publication bias and research on passive smoking: Comparison of published and unpublished studies. Journal of the American Medical Association, 280, 250-253.
97. Monbiot, G. (2002, May 14). The fake persuaders: Corporations are inventing people to rubbish their opponents on the internet. The Guardian. Retrieved from http://politics.guardian.co.uk/green/comment/0,9236,715160.00.html
98. Moher, D., Schulz, K. F., & Altman, D. G. (2001). The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials. Annals of Internal Medicine, 134, 657-662.
99. Moncrieff, J. (2001). Are antidepressants overrated? A review of methodological problems in antidepressant trials. Journal of Nervous and Mental Disorders, 189, 288-295.
100. Moncrieff, J., Wessely, S., & Hardy (2001). Antidepressants using active placebos (Cochrane review). Cochrane Database Systematic Review, 2, CD003012.
101. Moorman, P. G., Grubber, J., Millikan, R. C., & Newman, B. (2003). Antidepressant medications and their association with invasive breast cancer and carcinoma in situ of the breast. Epidemiology, 14, 307-314.
102. Moses, H., & Martin, J. B. (2001). Academic relationships with industry: A new model for biomedical research. Journal of the American Medical Association, 285, 933-935.
103. Moynihan, R. (2003a). The making of disease: Female sexual dysfunction, British Medical Journal, 326, 45-47.
104. Moynihan, R. (2003b). Who pays for the pizza? Redefining the relationships between doctors and drug companies: 1. Entanglement. British Medical Journal, 326, 1189-1192.
105. Moynihan, R. (2003c). Who pays for the pizza? Redefining the relationships between doctors and drug companies: 2. Disentanglement. British Medical Journal, 326, 1193-1196.
106. Moynihan, R., Bero, L., Ross-Degnan, D., Henry, D., Lee, K., Watkins, J., et al. (2000). Coverage by the news media of the benefits and risks of medications. New England Journal of Medicine, 342, 1645-1650.
107. Nathan, D. G., & Weatherall, D. J. (2002). Academic freedom in clinical research. New England Journal of Medicine, 347, 1368-1371.
108. Otto, M. W., & Nierenberg, A. A. (2002). Assay sensitivity, failed clinical trials, and the conduct of science. Psychotherapy and Psychosomatics, 71, 241-243.
109. O'Meara, K. P. (2003, April 28). Putting power back in parental hands. Retrieved October 31, 2003, from http://www.insightmag.com/news/426722.html
110. Pellegrino, E. D., & Relman, A. S. (1999). Professional medical associations: Ethical and practical guidelines. Journal of the American Medical Association, 282, 984-986.
111. Petersen, M. (2002a, August 11). Heartfelt advice, hefty fees. The New York Times, p. C1.
112. Petersen, M. (2002b, November 22). Madison Ave. plays growing role in drug research, The New York Times, p. A1.
113. Petersen, M. (2003a, May 30). Court papers suggest scale of drug's use. The New York Times, p. C1.
114. Petersen, M. (2003b, March 12). Pfizer nears drug settlement. The New York Times, p. C1.
115. Petersen, M. (2003c, May 7). A respected face, but is it news or an ad? The New York Times, p. C1.
116. Pfeiffer, M. B. (2001, June 10). Drug marketing is widespread, Pough-keepsie Journal, p. A2.
117. Piasecki, M., Antonuccio, D. O., Steinagel, O., & Kohlenberg (2002). Penetration of the blind in a controlled study of Paxil used to treat cocaine addiction. Journal of Behavior Therapy and Experimental Psychiatry, 33, 67-71.
118. Public Citizen. (2002). United Seniors Association: Hired guns for PhRMA and other corporate interests. Retrieved July 16, 2002, from http://www.citizen.org/pressroom/release.cfm?ID=1153.
119. Pushing drugs to doctors. (1992, February). Consumer Reports, 87-94.
120. Quick, J. (2001, December). Maintaining the integrity of the clinical evidence base. Bulletin of the World Health Organization, 01-1602.
121. Quitkin, F. M. (1999). Placebos, drug effects, and study design: A clinician's guide. American Journal of Psychiatry, 156, 829-836.
122. Relman, A. S. (2003). Defending professional independence: ACCME's proposed new guidelines for commercial support of CME. Journal of the American Medical Association, 289, 2418-2420.
123. Relman, A. S., & Angell, M. (2002, December 16). America's other drug problem: How the drug industry distorts medicine and politics. The New Republic, 27-41.
124. Rennie, D. (1997). Thyroid storm. Journal of the American Medical Association, 277, 1238-1243.
125. Rennie, D. (1999). Fair conduct and fair reporting of clinical trials. Journal of the American Medical Association, 282, 1766-1768.
126. Rosenthal, M. B., Berndt, E. R., Donohue, J. M., Frank, R. G., & Epstein, A. M. (2002). Promotion of prescription drugs to consumers. New England Journal of Medicine, 346, 498-505.
127. Ross, J., Lurie, P., & Wolfe, S. M. (2000). Letter to the accreditation council for graduate medical education regarding a Public Citizen study describing medical education services suppliers (HRG Publication No. 1530). The Health Research Group. Retrieved July 25 from http://www.citizen.org/publications/release.cfm?ID=6731.
128. Safer, D. (2002). Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. Journal of Nervous and Mental Disease, 190, 583-592.
129. Schulman, K. A., Seils, D. M., Timbie, J. W., Sugarman, J., Dame, L. A., Weinfurt, K. P., et al. (2002). A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors. New England Journal of Medicine, 347, 1335-1341.
130. Seglin, J. L. (2002, August 18). Just saying no to gifts from drug makers. The New York Times. Retrieved from http://www.nytimes.com/2002/08/18/business/yourmoney/18ETHI.html?ei=5070&en= 9fb289c 1a7c032ae&ex=1063339200&pagewanted=print&position=top
131. Sigelman, D. W. (2002). Dangerous medicine. The American Prospect, 13, 30-32. Retrieved from http://www.prospect.org/print/V13/17/sigelman-d.html
132. Silverstein, K. (1999, December). Prozac.org: An influential mental health nonprofit finds its "grassroots" watered by pharmaceutical millions. Mother Jones. Retrieved from http://www.motherjones.com/mother_jones/ND99/nami.html
133. Steinbrook, R. (2000). Medical journals and medical reporting. New England Journal of Medicine, 342, 1668-1671.
134. Stolberg, S. G., & Gerth, J. (2000, November 16). High-tech stealth being used to sway doctor prescriptions. The New York Times. Retrieved from http://home.cwru.edu/activism/READ/NYT111600.html
135. Tanner, L. (2003, January 17). Training or marketing: Drug sales reps sitting in on exams. The Associated Press. Retrieved from http://www.drugawareness.org/Archives/1stQtr_2003/record0022.html
136. Templeton, S. K. (2002, June 23). Drug companies and charities accused of conflict of interest. Edinburgh Sunday Herald. Retrieved from http://www.sundayherald.com/25686
137. Thase, M. E. (1999). How should efficacy be evaluated in randomized clinical trials of treatments for depression? Journal of Clinical Psychiatry, 60 (Suppl. 4), 23-31.
138. The Lancet. (2001). Editorial: The tightening grip of big Pharma. The Lancet, 357, 1141.
139. Torrey, E. F. (2002), The going rate on shrinks: Big Pharma and the buying of psychiatry. The American Prospect, 13. Retrieved from http://www.prospect.org/print/V13/13/torrey-e.html
140. Vedantam, S. (2001, July 16). Drug ads hyping anxiety make some uneasy. The Washington Post, p. A1.
141. Vedantam, S. (2002, May 26). Industry role in medical meeting decried: Symposiums sponsored by pharmaceutical companies trouble some psychiatrists. The Washington Post, p. A10.
142. Vergano, D. (2001, May 16). Filed under F (for forgotten). USA Today. Retrieved from http://www.usatoday.com/news/health/2001-05-17-drug-companies.htm
143. Villanueva, P., Peiro, S., Librero, J., & Pereiro, I. (2003). Accuracy of pharmaceutical advertisements in medical journals. Lancet, 361, 27-32.
144. Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002). Placebo response in studies of major depression. Journal of the American Medical Association, 287, 1840-1847.
145. Watkins, C., Moore, L., Harvey, I., Carthy, P., Robinson, E., & Brawn, R. (2003). Characteristics of general practitioners who frequently see drug industry representatives: National cross sectional study. British Medical Journal, 326, 1178-1179.
146. Wazana, A. (2000). Physicians and the pharmaceutical industry: Is a gift ever just a gift? Journal of the American Medical Association, 283, 373-380.
147. Wayne, L., & Petersen, M. (2001, November 4). Drug industry: A muscular lobby tries to shape nation's bioterror plan. The New York Times, Section 3, p. 1. Retrieved from http://query.nytimes.com/search/abstract?res=F10814FE3D5D0C778CDDA80994D9404482
148. White, K., Kando, J., Park, T., Waternaux, C., & Brown, W. A. (1992). Side effects and the "blindability" of clinical drug trials. American Journal of Psychiatry, 149, 1730-1731.
149. Wilkes, M. S., Doblin, B. H., & Shapiro, M. F. (1992). Pharmaceutical advertisements in leading medical journals: Experts assessments. Annals of Internal Medicine 116, 912-919.
150. Willman, D. (2000, Decembsr 20). How a new policy led to seven deadly drugs. Los Angeles Times, p. A1. Retrieved from http://www.latimes.rethinking.org/aids/LATimes/SevenDeadlyDrugs_12202000.htm
151. Wise, P., & Drury, M. (1995). Pharmaceutical trials in general practice: The first 100 protocols: An audit by the clinical research ethics committee of the Royal College of General Practitioners. British Medical Journal, 313, 1245-1248.
152. Wolfe, S. (2002). Direct-to-consumer advertising: Education or emotion promotion? New England Journal of Medicine, 346, 524-526.
153. Woloshin, S., & Schwartz (2002). Press releases: Translating research into news. Journal of the American Medical Association, 287, 2856-2858.
154. Ziegler, M. G., Lew, P., & Singer, B. C. (1995). The accuracy of drug information from pharmaceutical sales representatives. Journal of the American Medical Association, 273, 1296-1298.